beraprost and Lung-Neoplasms

beraprost has been researched along with Lung-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for beraprost and Lung-Neoplasms

ArticleYear
Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis.
    International journal of oncology, 2015, Volume: 46, Issue:2

    Prostaglandin I2 (PGI2) agonist has been reported to reduce tumor metastasis by modifying tumor angiogenesis; however, the mechanisms of how PGI2 affects the endothelial cells or pericytes in tumor vessel maturation are still unclear. The purpose of this study was to clarify the effects of PGI2 on tumor metastasis in a mouse lung metastasis model using Lewis lung carcinoma (LLC) cells. The mice were treated continuously with beraprost sodium (BPS), a PGI2 analog, for 3 weeks and then examined for lung metastases. The number and size of lung metastases were decreased significantly by BPS treatment. In addition, scanning electron microscopy and immunohistochemistry revealed that BPS increased the number of tumor‑associated pericytes and improved intratumor hypoxia. Collectively, this study suggests that BPS attenuated vascular functional maturation in metastatic tumors.

    Topics: Animals; Blood Vessels; Carcinoma, Lewis Lung; Epoprostenol; Humans; Lung Neoplasms; Mice; Neovascularization, Pathologic; Pericytes

2015
[Unexplained pulmonary arterial hypertension in a patient with lung resection, treated with sildenafil and beraprost].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2006, Volume: 44, Issue:11

    A 70-year-old man with a past history of lung resection for early stage lung cancer was admitted to our hospital because of worsening exertional dyspnea. Right heart catheterization revealed severe pulmonary arterial hypertension (PAH) with pulmonary vascular resistance of 1671.64 dyne.sec.cm(-5). The patient was treated with sildenafil added to an oral prostacyclin analog, beraprost, and long term oxygen therapy. His exertional dyspnea continued to improve until his sudden death following nasal bleeding. Autopsy revealed marked thickening of pulmonary arteriolar walls, but no recurrence of lung cancer, significant pulmonary embolism or pulmonary parenchymal disease. His PAH could not be explained by the mild airway obstruction or sleep apnea syndrome, and unrelated pulmonary vascular disease was suspected.

    Topics: Aged; Epoprostenol; Humans; Hypertension, Pulmonary; Lung Neoplasms; Male; Oxygen Inhalation Therapy; Phosphodiesterase Inhibitors; Piperazines; Pneumonectomy; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfones; Vascular Resistance

2006